{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:10:30Z","timestamp":1790644230884,"version":"4.1.0"},"reference-count":63,"publisher":"Xia & He Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,28]]},"DOI":"10.14218\/jcth.2020.00023","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T23:34:26Z","timestamp":1598225666000},"page":"1-9","source":"Crossref","is-referenced-by-count":31,"title":["Antihepatic Fibrosis Drugs in Clinical Trials"],"prefix":"10.14218","volume":"8","author":[{"given":"Yue-Cheng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun-Gen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"key20200823233420_b1","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J Hepatol"},{"key":"key20200823233420_b2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"key20200823233420_b3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol Rev"},{"key":"key20200823233420_b4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jso.21613","article-title":"Mechanical stiffness of liver tissues in relation to integrin \u03b21 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma","volume":"102","author":"Zhao","year":"2010","journal-title":"J Surg Oncol"},{"key":"key20200823233420_b5","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"key20200823233420_b6","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: a translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"key20200823233420_b7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0036-1597816","article-title":"Regression of liver fibrosis","volume":"37","author":"Campana","year":"2017","journal-title":"Semin Liver Dis"},{"key":"key20200823233420_b8","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20200823233420_b9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"key20200823233420_b10","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"key20200823233420_b11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"key20200823233420_b12","first-page":"657","article-title":"Consensus on the diagnosis and therapy of hepatic fibrosis in","volume":"27","author":"Chinese Society of Hepatology Chinese Medical Association; Chinese Society of Gastroenterology Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"key20200823233420_b13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: Role of scoring systems","volume":"22","author":"Goel","year":"2018","journal-title":"Clin Liver Dis"},{"key":"key20200823233420_b14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"key20200823233420_b15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"key20200823233420_b16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"key20200823233420_b17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"key20200823233420_b18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease","volume":"53","author":"Porez","year":"2012","journal-title":"J Lipid Res"},{"key":"key20200823233420_b19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"key20200823233420_b20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"key20200823233420_b21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"key20200823233420_b22","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"key20200823233420_b23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/hep.26786","article-title":"Bile acids reach out to the spinal cord: new insights to the pathogenesis of itch and analgesia in cholestatic liver disease","volume":"59","author":"Dawson","year":"2014","journal-title":"Hepatology"},{"key":"key20200823233420_b24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/13543784.2017.1371135","article-title":"Investigational drugs in phase II clinical trials for primary biliary cholangitis","volume":"26","author":"Silveira","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"key20200823233420_b25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel non-bile acid FXR agonist tropifexor (LJN452) in healthy volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key20200823233420_b26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"key20200823233420_b27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"key20200823233420_b28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"key20200823233420_b29","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J Biol Chem"},{"key":"key20200823233420_b30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"key20200823233420_b31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ajg.2015.20","article-title":"A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia","volume":"110","author":"Hosonuma","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"key20200823233420_b32","first-page":"2757","article-title":"Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"key20200823233420_b33","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"key20200823233420_b34","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.2353\/ajpath.2009.080632","article-title":"Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice","volume":"174","author":"Mitchell","year":"2009","journal-title":"Am J Pathol"},{"key":"key20200823233420_b35","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1002\/jcp.26485","article-title":"Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell line","volume":"233","author":"Coppola","year":"2018","journal-title":"J Cell Physiol"},{"key":"key20200823233420_b36","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"key20200823233420_b37","doi-asserted-by":"crossref","first-page":"e0005137","DOI":"10.1371\/journal.pntd.0005137","article-title":"Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis","volume":"11","author":"de Oliveira","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"key20200823233420_b38","doi-asserted-by":"crossref","first-page":"e75361","DOI":"10.1371\/journal.pone.0075361","article-title":"Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"key20200823233420_b39","doi-asserted-by":"crossref","first-page":"e83481","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"key20200823233420_b40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key20200823233420_b41","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"key20200823233420_b42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"key20200823233420_b43","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"key20200823233420_b44","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"key20200823233420_b45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2015.03.019","article-title":"Inhibitor of apoptosis signal-regulating kinase 1 protects against acetaminophen-induced liver injury","volume":"286","author":"Xie","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"key20200823233420_b46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"key20200823233420_b47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension","volume":"69","author":"Garcia-Tsao","year":"2019","journal-title":"Hepatology"},{"key":"key20200823233420_b48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20200823233420_b49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1440-1681.2009.05194.x","article-title":"Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells","volume":"36","author":"Zhao","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key20200823233420_b50","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1136\/gut.2006.107136","article-title":"A pilot study in patients with established advanced liver fibrosis using pirfenidone","volume":"55","author":"Armend\u00e1riz-Borunda","year":"2006","journal-title":"Gut"},{"key":"key20200823233420_b51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"key20200823233420_b52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13318-015-0316-z","article-title":"Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study","volume":"42","author":"Liu","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"key20200823233420_b53","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat Med"},{"key":"key20200823233420_b54","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","article-title":"Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal","volume":"66","author":"Ikenaga","year":"2017","journal-title":"Gut"},{"key":"key20200823233420_b55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"key20200823233420_b56","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.13177","article-title":"Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial","volume":"36","author":"Meissner","year":"2016","journal-title":"Liver Int"},{"key":"key20200823233420_b57","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: Phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"key20200823233420_b58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3904\/kjim.2017.317","article-title":"Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension","volume":"33","author":"Shim","year":"2018","journal-title":"Korean J Intern Med"},{"key":"key20200823233420_b59","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.3748\/wjg.v12.i42.6786","article-title":"Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C","volume":"12","author":"Yoshiji","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key20200823233420_b60","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-003-1222-8","article-title":"Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity","volume":"38","author":"Baik","year":"2003","journal-title":"J Gastroenterol"},{"key":"key20200823233420_b61","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"key20200823233420_b62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1478-3231.2012.02774.x","article-title":"Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int"},{"key":"key20200823233420_b63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12072-018-9897-3","article-title":"Antifibrotics in liver disease: are we getting closer to clinical use?","volume":"13","author":"Bansal","year":"2019","journal-title":"Hepatol Int"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2020.00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:19Z","timestamp":1783707559000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2020.00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,8,24]]},"published-print":{"date-parts":[[2020,9,28]]}},"alternative-id":["10.14218\/JCTH.2020.00023"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00023","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]}}}